Nicholas A. Butowski, MD

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Nicholas A. Butowski, MD

Professor, Neurological Surgery
Director, Translational Research, Neuro-Oncology
Director, UCNS Fellowship, Neuro-Oncology
Chair, CNS Tumors Site Committee, UCSF Helen Diller Family Comprehensive Cancer Center

Phone: (415) 353-2966 (appts)
Box 0372, UCSF
San Francisco, CA 94143-0372

Cancer Center Membership

Program Member » Neurologic Oncology

Research Summary

Dr. Butowski specializes in novel therapeutic approaches to brain tumors, clinical trials, neuro-imaging, cognitive and rehabilitative neurology, medical education, and complementary therapy. His ultimate research goal is to develop novel and effective therapeutic strategies for the treatment of patients with primary brain tumors. The most direct research application is the design and conduct of phase I, II, and III clinical trials, and Dr. Butowski is a co-investigator of National Cancer Institute-supported North American Brain Tumor Consortium clinical trials. As a member of the Brain Tumor Research Center at UCSF, his research goals have expanded to include the evaluation of novel imaging techniques and molecular profiling methods that may influence the selection of patients for treatment. His research interests also include methods and/or treatments to ensure good quality of life for patients with brain tumors and methods and/or treatments that may assist patients in recovering from or coping with brain injury. The majority of his clinical activities involve the assessment and management of adult patients with brain tumors.

Education

Northwestern University, Evanston, IL, BA, 1991-1995, Philosophy/Religion
University of Illinois at Chicago, Chicago, IL, MD, 1995-1999
Evanston-Northwestern Hospital, Evanston, IL, Surgical Intern, 1999-2000
UCSF Department of Neurology, Resident, 2000-2003
UCSF Department of Neurological Surgery, Neuro-Oncology Fellow, 2003-2004


Professional Experience

  • 2004-2004
    Clinical Instructor, Department of Neurological Surgery, UCSF
  • 2005-2010
    Assistant Clinical Professor, Department of Neurological Surgery, UCSF
  • 2010-2015
    Associate Clinical Professor, Department of Neurological Surgery, UCSF
  • 2015-present
    Professor, Department of Neurological Surgery, UCSF

Professional Membership and Appointments

American Academy of Neurology
Society for Neuro-Oncology
American Society of Clinical Oncology
International Society of Neuro-Oncology

Selected Publications

  1. Han SJ, Bankiewicz K, Butowski NA, Larson PS, Aghi MK. Interventional MRI-guided catheter placement and real time drug delivery to the central nervous system. Expert Rev Neurother. 2016 Apr 20:1-5. [Epub ahead of print] PubMed PMID: 27054877.
  2. Wen Q, Jalilian L, Lupo JM, Li Y, Roy R, Molinaro AM, Chang SM, Prados M, Butowski N, Clarke J, Nelson SJ. Association of Diffusion and Anatomic Imaging Parameters with Survival for Patients with Newly Diagnosed Glioblastoma Participating in Two Different Clinical Trials. Transl Oncol. 2015 Dec;8(6):446-55. doi: 10.1016/j.tranon.2015.10.001. PubMed PMID: 26692525; PubMed Central PMCID: PMC4700297.
  3. Imber BS, Braunstein SE, Wu FY, Nabavizadeh N, Boehling N, Weinberg VK, Tihan T, Barnes M, Mueller S, Butowski NA, Clarke JL, Chang SM, McDermott MM, Prados MD, Berger MS, Haas-Kogan DA. Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. J Neurooncol. 2016 Jan;126(1):193-200. PubMed PMID: 26493740; PubMed Central PMCID: PMC4826306.
  4. Han SJ, Butowski NA. In Reply: Survival With Glioblastoma Multiforme and the Timing of Chemoradiation. Neurosurgery. 2016 Feb;78(2):E315. doi: 10.1227/NEU.0000000000001078. PubMed PMID: 26492432.
  5. Nabors LB, Portnow J, Ammirati M, Baehring J, Brem H, Brown P, Butowski N, Chamberlain MC, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Holdhoff M, Junck L, Kaley T, Lawson R, Loeffler JS, Lovely MP, Moots PL, Mrugala MM, Newton HB, Parney I, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Weiss S, Wen PY, McMillian N, Engh AM. Central Nervous System Cancers, Version 1.2015. J Natl Compr Canc Netw. 2015 Oct;13(10):1191-202. PubMed PMID: 26483059.
  6. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr;18(4):557-64. doi: 10.1093/neuonc/nov245. Epub 2015 Oct 8. PubMed PMID: 26449250; PubMed Central PMCID: PMC4799682.
  7. Lupo JM, Molinaro AM, Essock-Burns E, Butowski N, Chang SM, Cha S, Nelson SJ. The effects of anti-angiogenic therapy on the formation of radiation-induced microbleeds in normal brain tissue of patients with glioma. Neuro Oncol. 2016 Jan;18(1):87-95. doi: 10.1093/neuonc/nov128. Epub 2015 Jul 22. PubMed PMID: 26206774; PubMed Central PMCID: PMC4677411.
  8. Han SJ, Englot DJ, Birk H, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. Impact of Timing of Concurrent Chemoradiation for Newly Diagnosed Glioblastoma: A Critical Review of Current Evidence. Neurosurgery. 2015 Aug;62 Suppl 1:160-5. doi: 10.1227/NEU.0000000000000801. Review. PubMed PMID: 26181937.
  9. Racine CA, Li J, Molinaro AM, Butowski N, Berger MS. Neurocognitive Function in Newly Diagnosed Low-grade Glioma Patients Undergoing Surgical Resection With Awake Mapping Techniques. Neurosurgery. 2015 Sep;77(3):371-9; discussion 379. doi: 10.1227/NEU.0000000000000779. PubMed PMID: 25930064.
  10. Han SJ, Rutledge WC, Molinaro AM, Chang SM, Clarke JL, Prados MD, Taylor JW, Berger MS, Butowski NA. The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma. Neurosurgery. 2015 Aug;77(2):248-53; discussion 253. doi: 10.1227/NEU.0000000000000766. PubMed PMID: 25856113; PubMed Central PMCID: PMC4506198.
  11. Butowski NA. Epidemiology and diagnosis of brain tumors. Continuum (Minneap Minn). 2015 Apr;21(2 Neuro-oncology):301-13. doi: 10.1212/01.CON.0000464171.50638.fa. Review. PubMed PMID: 25837897.
  12. Nabors LB, Portnow J, Ammirati M, Brem H, Brown P, Butowski N, Chamberlain MC, DeAngelis LM, Fenstermaker RA, Friedman A, Gilbert MR, Hattangadi-Gluth J, Hesser D, Holdhoff M, Junck L, Lawson R, Loeffler JS, Moots PL, Mrugala MM, Newton HB, Raizer JJ, Recht L, Shonka N, Shrieve DC, Sills AK Jr, Swinnen LJ, Tran D, Tran N, Vrionis FD, Wen PY, McMillian NR, Ho M. Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw. 2014 Nov;12(11):1517-23. PubMed PMID: 25361798; PubMed Central PMCID: PMC4337873.
  13. Yoshida Y, Ozawa T, Yao TW, Shen W, Brown D, Parsa AT, Raizer JJ, Cheng SY, Stegh AH, Mazar AP, Giles FJ, Sarkaria JN, Butowski N, Nicolaides T, James CD. NT113, a pan-ERBB inhibitor with high brain penetrance, inhibits the growth of glioblastoma xenografts with EGFR amplification. Mol Cancer Ther. 2014 Dec;13(12):2919-29. doi: 10.1158/1535-7163.MCT-14-0306. Epub 2014 Oct 13. PubMed PMID: 25313012; PubMed Central PMCID: PMC4364529.
  14. Mrugala MM, Engelhard HH, Dinh Tran D, Kew Y, Cavaliere R, Villano JL, Annenelie Bota D, Rudnick J, Love Sumrall A, Zhu JJ, Butowski N. Clinical practice experience with NovoTTF-100A™ system for glioblastoma: The Patient Registry Dataset (PRiDe). Semin Oncol. 2014 Oct;41 Suppl 6:S4-S13. doi: 10.1053/j.seminoncol.2014.09.010. Epub 2014 Sep 16. Erratum in: Semin Oncol. 2015 Jun;42(3):e33-43. PubMed PMID: 25213869.
  15. Osorio JA, Hervey-Jumper SL, Walsh KM, Clarke JL, Butowski NA, Prados MD, Berger MS. Familial gliomas: cases in two pairs of brothers. J Neurooncol. 2015 Jan;121(1):135-40. doi: 10.1007/s11060-014-1611-2. Epub 2014 Sep 11. PubMed PMID: 25208478.
  16. Lacouture ME, Davis ME, Elzinga G, Butowski N, Tran D, Villano JL, DiMeglio L, Davies AM, Wong ET. Characterization and management of dermatologic adverse events with the NovoTTF-100A System, a novel anti-mitotic electric field device for the treatment of recurrent glioblastoma. Semin Oncol. 2014 Jun;41 Suppl 4:S1-14. doi: 10.1053/j.seminoncol.2014.03.011. Epub 2014 Mar 19. PubMed PMID: 24794308.
  17. Andersson U, Wibom C, Cederquist K, Aradottir S, Borg A, Armstrong GN, Shete S, Lau CC, Bainbridge MN, Claus EB, Barnholtz-Sloan J, Lai R, Il'yasova D, Houlston RS, Schildkraut J, Bernstein JL, Olson SH, Jenkins RB, Lachance DH, Wrensch M, Davis FG, Merrell R, Johansen C, Sadetzki S; Gliogene Consortium, Bondy ML, Melin BS. Germline rearrangements in families with strong family history of glioma and malignant melanoma, colon, and breast cancer. Neuro Oncol. 2014 Oct;16(10):1333-40. doi: 10.1093/neuonc/nou052. Epub 2014 Apr 9. PubMed PMID: 24723567; PubMed Central PMCID: PMC4165415.
  18. Han SJ, Rolston JD, Molinaro AM, Clarke JL, Prados MD, Chang SM, Berger MS, DeSilva A, Butowski NA. Phase II trial of 7 days on/7 days off temozolmide for recurrent high-grade glioma. Neuro Oncol. 2014 Sep;16(9):1255-62. doi: 10.1093/neuonc/nou044. Epub 2014 Mar 26. PubMed PMID: 24670608; PubMed Central PMCID: PMC4136897.
  19. Clarke JL, Molinaro AM, Phillips JJ, Butowski NA, Chang SM, Perry A, Costello JF, DeSilva AA, Rabbitt JE, Prados MD. A single-institution phase II trial of radiation, temozolomide, erlotinib, and bevacizumab for initial treatment of glioblastoma. Neuro Oncol. 2014 Jul;16(7):984-90. PubMed PMID: 24637230; PubMed Central PMCID: PMC4057142.